

Corrigendum

Corrigendum to “Neuroprotective effects of olanzapine
in a rat model of neurodevelopmental injury”
[Pharmacol Biochem Behav 83 (2006) 208–213]

John G. Csernansky^{a,b,*}, Maureen V. Martin^a, Barry Czeisler^a, Mitchell A. Meltzer^a,
Zulfiqar Ali^a, Hongxin Dong^a

^a Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA

^b Department of Anatomy and Neurobiology, Washington University School of Medicine, St. Louis, MO 63110, USA

Available online 22 August 2006

The authors of the above article regret that Table 1 contained errors when originally published. The table is reproduced below in its correct format.

Drug administration	FJB-labeled cells ^a (mean±S.D.)	BrdU-labeled cells ^a (mean±S.D.)
Saline	38.1±33.5	69.4±42.0
Haloperidol (1.2 mg/kg)	47.1±33.2	132.6±104
Melatonin (10 mg/kg)	8.3±8.06	78.3±44.5
Olanzapine (2 mg/kg)	15.0±16.1	105.3±26.6
Olanzapine (6 mg/kg)	18.0±22.7	116.0±41.4
Olanzapine (12 mg/kg)	5.4±5.60	132.7±44.5

^a Number of FJB- and BrdU-positive cells per $\mu\text{m}^3 \times 10^5$. See text for location of histological sections.

DOI of original article: [10.1016/j.pbb.2006.01.009](https://doi.org/10.1016/j.pbb.2006.01.009).

* Corresponding author. Department of Psychiatry, Washington University School of Medicine, Campus Box 8134, 660 South Euclid Ave., St. Louis, MO 63110, USA. Tel.: +1 314 747 2160; fax: +1 314 747 2182.

E-mail address: jgc@contc.wustl.edu (J.G. Csernansky).

091-3057/\$ - see front matter © 2006 Elsevier Inc. All rights reserved.

doi:[10.1016/j.pbb.2006.07.016](https://doi.org/10.1016/j.pbb.2006.07.016)